En Carta Diagnostics
Business Services · France · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Paris, Ile-de-France, 75012, FranceWebsite
encarta.bioRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About En Carta Diagnostics
EnCarta Bio is a biotechnology company focused on developing innovative diagnostic solutions that enable faster and more accessible disease detection. The company is advancing next-generation testing technologies designed to provide accurate insights for healthcare providers and patients, with an emphasis on improving diagnostic decision-making and patient outcomes. EnCarta Bio’s work centers on applying biotechnology and scientific innovation to create practical tools that support earlier detection and better management of health conditions.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is En Carta Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if En Carta Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when En Carta Diagnostics launches new products
Click to see if En Carta Diagnostics had a recent Job posting/layoffs
Check out if En Carta Diagnostics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on En Carta Diagnostics recently announced quarterly report
Funding: Get notified immidiatlly once En Carta Diagnostics has new funding data
Congratulate Masked Content for being promoted to Masked Content at En Carta Diagnostics
En Carta Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined En Carta Diagnostics as Masked Content
Find more new buyers
En Carta Diagnostics financials insights
Gather financial insights about En Carta Diagnostics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$1.6M
2026
Private Equity
$3.4M
Other Financing Round
$2.3M
En Carta Diagnostics Tech Stack
Most Recent Scoops
Funding
Funding
Funding
Funding
Funding
Funding
En Carta Diagnostics News & Media
En Carta Diagnostics raises €5 million to bring at-home molecular tests for Lyme disease ...
En Carta Diagnostics, a Paris-based DeepTech startup developing a new generation of molecular diagnostics for use at home, has announced the first closingAAZ and En Carta Diagnostics Announce Strategic Partnership to Advance Rapid Decentralized STI Screening
Collaboration between AAZ and En Carta Diagnostics sees a new generation of molecular tests and self-tests dedicated to detection of chlamydia and gonorrhea. PARIS, FRANCE, May 21, 2026 /EINPresswire.com/ -- AAZ, the French pioneer in self-tests and …
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding En Carta Diagnostics
Sign Up For FreeTo access detailed company insights
EnCarta Bio is a biotechnology company focused on developing innovative diagnostic solutions that enable faster and more accessible disease detection. The company is advancing next-generation testing technologies designed to provide accurate insights for healthcare providers and patients, with an emphasis on improving diagnostic decision-making and... Read More
